ArticleFrontiers in immunology2022
Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Molecular dynamics simulations along with the synthesis of innovative engineered nanobodies targeting Interleukin-2.Molecular biology reports · 2026Article
- Cold Atmospheric Plasma-Activated In Situ Hydrogel Induces Hair Regeneration Via Immune Microenvironment Remodeling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- IL-15 in alopecia areata: the immune tolerance mechanistic insights and translational perspectives.Frontiers in medicine · 2026Review
- Human MAIT cells undergo clonal selection and expansion during thymic maturation and aging.Experimental & molecular medicine · 2025Article
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology.Frontiers in immunology · 2025Review
- Article
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches.Frontiers in immunology · 2025Review
- Tissue-specific roles of regulatory T cells: mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications.Frontiers in immunology · 2025Review
- Jagged-1+ skin Tregs modulate cutaneous wound healing.Scientific reports · 2024Article
- Treg-targeted IL-2/anti-IL-2 complex controls graft-Haematologica · 2024Article
- Regulatory T cells in skin regeneration and wound healing.Military Medical Research · 2023Review
- The potential of regulatory T cell-based therapies for alopecia areata.Frontiers in immunology · 2023Review
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions.Frontiers in immunology · 2023Review
- Targeted immunotherapy for hair regrowth and regeneration.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) is an autoimmune disease mediated by NKG2D-expressing cytotoxic T lymphocytes destroying hair follicles in the skin. It is one of the most common autoimmune diseases, but there is no effective treatment modality approved by the FDA. Regulatory T cells (Tregs) are crucial for suppressing autoreactive T cells, and in the skin, they promote hair growth by inducing anagen. Based on this, we tested the therapeutic potential of expanded Tregs in AA using the C3H/HeJ mouse model. In mice with AA, NKG2D-expressing CD8 T cells widely infiltrate both haired and hairless skin areas, which have tissue-resident memory T-cell phenotypes. Tregs in the skin express CD25, CTLA-4, GATA-3, and Jagged1 and efficiently proliferate with IL-2 cytokine antibody complex. However, expanding Tregs in the skin did not induce anagen in normal mice, indicating that they are necessary but not sufficient for anagen induction. Also, they fail to suppress autoreactive CD8 T cells in the skin to reverse established AA in C3H/HeJ mice. These results suggest that Treg expansion alone is not sufficient for AA treatment, and combined immunotherapy is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.